{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:01:20Z","timestamp":1784534480619,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","award":["RDL2023\\u201011"],"award-info":[{"award-number":["RDL2023\\u201011"]}],"id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015083","name":"Peking University People's Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015083","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370161"],"award-info":[{"award-number":["82370161"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970140"],"award-info":[{"award-number":["81970140"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.clml.2026.02.005","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T16:19:53Z","timestamp":1771258793000},"page":"309-316.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Olverembatinib-Based Therapy in Patients With Transformed Chronic Myeloid Leukemia in Lymphoid Blast Phase or Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Multicenter Retrospective Study"],"prefix":"10.1016","volume":"26","author":[{"given":"Mei","family":"Bao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongru","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linhua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congmeng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7131-0522","authenticated-orcid":false,"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.clml.2026.02.005_bib0001","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the Life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2026.02.005_bib0002","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","article-title":"2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"39","author":"Apperley","year":"2025","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2026.02.005_bib0003","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/s41375-024-02204-y","article-title":"Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry","volume":"38","author":"Brioli","year":"2024","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.clml.2026.02.005_bib0004","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/14737140.2020.1832890","article-title":"Treatment and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults after relapse","volume":"20","author":"Balsat","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clml.2026.02.005_bib0005","article-title":"A predictive model for therapy failure in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor therapy","author":"Zhang","year":"2024","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2026.02.005_bib0006","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of Imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J med"},{"key":"10.1016\/j.clml.2026.02.005_bib0007","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2020.12.022","article-title":"Long-term follow-up of blinatumomab in patients with relapsed\/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: final analysis of ALCANTARA study","volume":"146","author":"Martinelli","year":"2021","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.clml.2026.02.005_bib0008","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/ajh.25648","article-title":"Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors","volume":"94","author":"Abou Dalle","year":"2019","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.clml.2026.02.005_bib0009","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1182\/blood-2009-12-261586","article-title":"First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia","volume":"116","author":"Ravandi","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2026.02.005_bib0010","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1007\/s00277-024-05682-3","article-title":"Allogeneic stem cell transplantation is still a highly curative therapy in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia","volume":"103","author":"Hu","year":"2024","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.clml.2026.02.005_bib0011","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S2352-3026(21)00370-7","article-title":"Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1\/2 trial","volume":"9","author":"Copland","year":"2022","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1016\/j.clml.2026.02.005_bib0012","doi-asserted-by":"crossref","first-page":"e839","DOI":"10.1016\/S2352-3026(24)00250-3","article-title":"Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial","volume":"11","author":"Short","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2026.02.005_bib0013","article-title":"Olverembatinib (HQP1351)-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia in blast phase: results from a real-world study","volume":"16","author":"Wen","year":"2025","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.clml.2026.02.005_bib0014","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.clml.2026.02.005_bib0015","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.clml.2023.04.012","article-title":"Olverembatinib treatment in pediatric patients with relapsed Philadelphia-chromosome-positive acute lymphoblastic leukemia","volume":"23","author":"Li","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.clml.2026.02.005_bib0016","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2026.02.005_bib0017","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1080\/10428194.2020.1762876","article-title":"Ponatinib-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the real-life OPAL study","volume":"61","author":"Tavitian","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.clml.2026.02.005_bib0018","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1080\/10428194.2023.2197534","article-title":"Olverembatinib in relapsed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: a study of 5 cases","volume":"64","author":"Liu","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.clml.2026.02.005_bib0019","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1111\/bjh.19804","article-title":"Efficacy and safety of olverembatinib in adult BCR:ABL1-positive ALL with T315I mutation or relapsed\/refractory disease","volume":"205","author":"Liu","year":"2024","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.clml.2026.02.005_bib0020","first-page":"2986","article-title":"Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia","volume":"110","author":"Zhang","year":"2025","journal-title":"Haematologica"},{"issue":"Supplemental 1","key":"10.1016\/j.clml.2026.02.005_bib0021","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/blood-2022-162387","article-title":"Olverembatinib (HQP1351) overcomes ponatinib resistance in patients with heavily pretreated\/refractory chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"140","author":"Jabbour","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2026.02.005_bib0022","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/ajh.70026","volume":"100","author":"Zhang","year":"2025","journal-title":"Am J Hematol"},{"issue":"19","key":"10.1016\/j.clml.2026.02.005_bib0023","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood.2023020794","article-title":"Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel","volume":"143","author":"G\u00f6kbuget","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.02.005_bib0024","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13045-018-0564-x","article-title":"The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology","volume":"11","author":"Xu","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.02.005_bib0025","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13045-021-01159-2","article-title":"The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update","volume":"14","author":"Zhang","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"9","key":"10.1016\/j.clml.2026.02.005_bib0026","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.leukres.2013.06.003","article-title":"Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?","volume":"37","author":"Qin","year":"2013","journal-title":"Leuk Res"},{"issue":"7","key":"10.1016\/j.clml.2026.02.005_bib0027","first-page":"433","article-title":"Detection of common fusion transcript levels in untreated leukemia patients by real-time quantitative RT-PCR technique]","volume":"28","author":"Qin","year":"2007","journal-title":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi"},{"issue":"7","key":"10.1016\/j.clml.2026.02.005_bib0028","doi-asserted-by":"crossref","first-page":"E229","DOI":"10.1002\/ajh.26175","article-title":"An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"96","author":"Short","year":"2021","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.clml.2026.02.005_bib0029","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1002\/ajh.27329","article-title":"Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy","volume":"99","author":"Short","year":"2024","journal-title":"Am J Hematol"},{"issue":"22","key":"10.1016\/j.clml.2026.02.005_bib0030","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/cncr.30864","article-title":"Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.clml.2026.02.005_bib0031","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1002\/cncr.33539","article-title":"Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib","volume":"127","author":"Morita","year":"2021","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.clml.2026.02.005_bib0032","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3324\/haematol.2009.014274","article-title":"Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group","volume":"95","author":"Oriol","year":"2010","journal-title":"Haematologica"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:01:25Z","timestamp":1784530885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026000406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2152265026000406"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.02.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Olverembatinib-Based Therapy in Patients With Transformed Chronic Myeloid Leukemia in Lymphoid Blast Phase or Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Multicenter Retrospective Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}